Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · February 16, 2021

First-Line BRAF/MEK Inhibitors vs Anti–PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
First-Line BRAF/MEK Inhibitors Versus Anti-PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma Patients: A Propensity-Matched Survival Analysis
Br. J. Cancer 2021 Jan 26;[EPub Ahead of Print], J van Breeschoten, MWJM Wouters, DL Hilarius, JB Haanen, CU Blank, MJB Aarts, FWPJ van den Berkmortel, JB de Groot, GAP Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, WAM Blokx, BJT Tije, AAMV Veldt, A Vreugdenhil, MJ Boers-Sonderen, AJM van den Eertwegh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading